Combination of tazaloparib and enzalutamide safe and effective in metastatic castration-resistant prostate cancer

According to a recent study conducted in males with metastatic castration-resistant prostate cancer (mCRPC), it was found that tazaloparib plus enzalutamide is safe and effective for treatment. This study’s results were published in the journal, Lancet.

TALAPRO-2 was a phase 3, randomized, double-blind, multicenter trial, enrolling 805 patients. Participants were prospectively assessed for homologous recombination repair (HRR) gene alterations in the tumor tissue and were randomly assigned in 1:1 ratio (orally once daily) to receive 0.5 mg talazoparib plus 160 mg enzalutamide (n=402) or 0.5 mg placebo plus 160 mg enzalutamide (n=403). The primary outcome of the study was radiographic progression free survival (rPFS).

The median follow-up for rPFS was 24.9 months and 24.6 months for the tazaloparib and placebo group, respectively. On primary analysis, median rPFS was not attained in the talazoparib group and it was 21.9 months for the placebo group. From the results obtained above, it may be concluded that there was significant clinical and statistical improvement seen in patients on talazoparib and enzalutamide as first-line treatment for mCRPC and is safe and effective for use.